
Please try another search
By Sam Boughedda
Mizuho analysts said in a note on medtech and diagnostics stocks on Thursday that the firm's top longs include Alcon (NYSE:ALC), Cooper Companies (NYSE:COO) and Medtronic (NYSE:MDT).
The analysts said in the memo to clients that they see many of the same themes from this year lingering into 2023, including "1) hospital health, 2) recession fears, and 3) inflation."
Conversely, they also believe the "pump feels primed for several tailwinds that could drive valuations higher," such as improving procedure volumes, a larger-scale M&A, and the return of the IPO market.
"We are launching coverage on Alcon (ALC, $85) and Cooper Companies (COO, $375) at Buy with both ratings reflecting the benefits to ophthalmology proving relatively more insular to other areas of Medtech in prior recessions coupled with benefits of recent/ongoing product launches providing tailwinds into next year," the analysts added.
"Our preferred large-cap names are ALC, COO and MDT, given we see: 1) ample portfolio balance for recession, 2) new product launches (e.g. RDN, IOP drops, MiSight), 3) exposure to high-growth end-markets (e.g. Glaucoma, TAVR, LAA, robotics), and [4]3) multiple R&D shots-on-goal over next 3-years."
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.